WISE GUY RESEARCH CONSULTANTS PVT LTD
Soluble Epoxide Hydrolase – Pipeline Review, H1 2016’, provides in depth analysis on Soluble Epoxide Hydrolasetargeted pipeline therapeutics.
PUNE, MAHARASHTRA, INDIA, June 17, 2016 /EINPresswire.com/ — Access Report: https://www.wiseguyreports.com/reports/soluble-epoxide-hydrolase-epoxide-hydratase-or-review-h1-2016
Summary
The report provides comprehensive information on the Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) – Companies Involved in Therapeutics Development 19
• GlaxoSmithKline Plc 19
• Sphaera Pharma Pvt. Ltd. 20
• Sumitomo Dainippon Pharma Co., Ltd. 21
• Toray Industries, Inc. 22
• Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) – Drug Profiles 23
• (diclofenac sodium + triclocarban) – Drug Profile 23
• Product Description 23
• Mechanism Of Action 23
• RD Progress 23
• EC-5026 – Drug Profile 24
• Product Description 24
• Mechanism Of Action 24
• RD Progress 24
• GSK-2256294 – Drug Profile 25
• Product Description 25
• Mechanism Of Action 25
RD Progress 25
Learn more from Sample Report @ https://www.wiseguyreports.com/sample-request/soluble-epoxide-hydrolase-epoxide-hydratase-or-review-h1-2016
Scope
– The report provides a snapshot of the global therapeutic landscape for Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10)
– The report reviews Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
– The report reviews key players involved in Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics and enlists all their major and minor projects
– The report assesses Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Check Special Discount@ https://www.wiseguyreports.com/check-discount/soluble-epoxide-hydrolase-epoxide-hydratase-or-review-h1-2016
Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here
